We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis.